Coenen, MJ

Donn, RP

Eijsbouts, AE

Fransen, J

Radstake, TR

Toonen, EJ

van, den Hoogen FH

van, Riel PL.

Introduction: Macrophage migration inhibiting factor (MIF) is an inflammatory mediator associated with RA severity. In various diseases MIF polymorphisms are associated with clinical response to glucocorticoid (GC) therapy. It is unclear whether MIF polymorphisms determine GC response in RA and to other RA therapies. Therefore, we studied whether two functional variants in MIF are associated with the response to GC and TNF-alpha neutralizing therapies in RA. METHODS: Data from two cohorts of an RA registry were used. For patients who started with GC or TNF-alpha neutralising (Infliximab) treatment, courses with a duration of at least three months were included and response to GC or TNF-alpha blockers was calculated according to the EULAR response criteria. MIF-173G&gt;C genotyping was achieved using an Assay-on-Demand allelic discrimination assay and alleles of the CATT repeat element were identified using a fluorescently labeled PCR primer and capillary electrophoresis. Logistic regression modelling was used for the statistical analysis. RESULTS: 192 courses of oral prednisone or methylprednisolone injections in 98 RA patients, and 90 RA patients on TNF-alpha neutralising therapies were documented. 27% of the RA patients was found to be heterozygous for CATT7 whereas 31% of them were heterozygous for -173C. Four and six percent of the RA patients were homozygous for the MIF CATT7 repeat or MIF -173C allele. Neither carrier ship nor homozygosity for CATT7 repeat nor MIF -173C allele of MIF was associated with response to GC (Odds ratios close to 1) or TNFalpha neutralising therapy (OR's close to 2). CONCLUSION: The MIF-CATT7 repeat and the MIF-173G&gt;C functional variant are not strongly associated with a decreased clinical response to GC or TNF-alpha neutralising therapy in RA

The University of Manchester - Institutional Repository

Macrophage migration inhibitory factor (MIF) polymorphisms do not predict therapeutic response to glucocorticoids or TNF-{alpha}neutralising therapies in rheumatoid arthritis.

Macrophage migration inhibitory factor (MIF) polymorphisms do not predict therapeutic response to glucocorticoids or TNF-{alpha}neutralising therapies in rheumatoid arthritis.

Abstract

Similar works

Full text

Available Versions

The University of Manchester - Institutional Repository